Uterine Papillary Serous Cancer (UPSC) Trial

Q

Queensland Centre for Gynaecological Cancer

Status and phase

Completed
Phase 2

Conditions

Uterine Cancer

Treatments

Drug: Paclitaxel, Carboplatin

Study type

Interventional

Funder types

Other

Identifiers

NCT00147680
UPSC - 001

Details and patient eligibility

About

This study will be an open, non-randomised, clinical phase 2 trial, which will involve 30 women diagnosed with uterine papillary serous cancer. The researchers will investigate the effect of four cycles of paclitaxel/carboplatin, followed by whole pelvic external beam radiotherapy to a standard pelvis field (50.4 Gy) with or without a para-aortic boost with respect to the safety and efficacy of treatment, and patterns of recurrence.

Full description

Trial Objectives: To assess the safety and efficacy of the combination of Paclitaxel and Carboplatin +/- pelvic radiotherapy in the treatment of UPSC. To observe the patterns of recurrence following the administration of the combination of Paclitaxel and Carboplatin +/- pelvic radiotherapy in the treatment of UPSC. To assess the QOL, overall survival and disease free survival. Treatment Surgery: Total abdominal hysterectomy, bilateral salpingo-oophorectomy, +/- pelvic and aortic node sampling, omentectomy, peritoneal cytology. Chemotherapy: Chemotherapy commences at the surgeon's and the medical oncologist's discretion and the time between surgery and start of chemotherapy will be recorded. One treatment cycle consists of 3 weeks. Paclitaxel and Carboplatin will be administered as follows: Day 1: Diphenhydramine 50 mg IV or po or phenergan 12.5 - 25 mg IV Cimetidine 300 mg or ranitidine 50 mg IV Dexamethasone 20 mg IV Paclitaxel 175 mg/m2 Carboplatin AUC 6 Day 22: Repeat the cycle. This is Day 1 of the second cycle. Day 43: Repeat the cycle. This is Day 1 of the third cycle. Day 64: Repeat the cycle. This is Day 1 of the fourth cycle. Day 85: After the fourth cycle of chemotherapy patients Patients with stage 4 disease will continue with chemotherapy for a total of 6 cycles. Patients with surgical stage 1b to 3c disease will receive whole pelvis external beam radiotherapy (50.4 Gy RD over 5 and a half weeks +/- paraaortic boost +/- vaginal vault brachytherapy boost). Radiotherapy will start 4 to 6 weeks after commencement of chemotherapy when the haematological count has recovered.

Enrollment

30 estimated patients

Sex

Female

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients with histologically confirmed UPSC at surgical stage 1b to 4 disease. The serous-papillary component of the specimen must be at least 30 percent. Patients with surgical stage 1a disease should not be enrolled.
  • Females aged >= 18 years old.
  • Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2.
  • Patients may not have received any prior chemotherapy regimens for UPSC.
  • Patients must have adequate bone marrow, renal, hepatic and neurologic function.
  • Patients must be informed of the investigational nature of the study and sign an informed consent form.
  • Patients with previous malignancy are eligible only if the patient has been disease-free for >= 5 years.

Exclusion criteria

  • Patients with pre-existing >= grade 2 neurotoxicity.
  • Patients with uncontrolled hypertension, (systolic blood pressure >180 mm Hg or diastolic blood pressure >100 mm Hg) or uncontrolled cardiac arrhythmia or diabetes mellitus
  • Patients with a history of other malignancy within the last 5 years that could affect the diagnosis or assessment of UPSC.
  • Patients who have a history of serious cardiac disease that is not adequately controlled are not allowed. Patients with documented myocardial infarction within 6 months preceding study entry; congestive heart failure; unstable angina; a clinically significant pericardial effusion; or arrhythmias are also ineligible.
  • Patients with an active serious infection or other serious underlying medical condition that would otherwise impair their ability to receive protocol treatment.
  • Serious medical or psychiatric illnesses that would prevent informed consent. Dementia or significantly altered mental status that would prohibit the understanding and/or giving of informed consent.
  • Patients with prior significant allergic reactions to drugs containing cremophor, such as cyclosporine, or vitamin K are not eligible. A significant reaction may be defined as, but is not limited to, the description of grade >= 3 allergic reactions using the Common Toxicity Criteria (CTC). Patients with known hypersensitivity to paclitaxel, carboplatin or Cremophor EL.
  • Patients who have received prior whole pelvis radiotherapy.
  • Patients with uncontrolled pelvic inflammatory disease that would contraindicate pelvic radiotherapy.
  • Patients who are pregnant or breast-feeding.
  • Patients receiving other investigational therapy.

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Single Group Assignment

Masking

None (Open label)

Trial contacts and locations

2

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems